1015 Capital Partners’s AbbVie ABBV Stock Holding History

1015 Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$365K	Sell	1,450 -13	-0.9%	-$2.8K	0.31%	59
2026 Q1	$318K	Buy	1,463 +12	+0.8%	+$2.66K	0.31%	59
2025 Q4	$332K	Buy	+1,451	New	+$331K	0.33%	57

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

1015 Capital Partners's ABBV Position: Q2 2026 in Review

1015 Capital Partners reduced its AbbVie (ABBV) stake by 0.89% in Q2 2026, selling an estimated $2.8K and leaving 1,450 shares worth $365K. The position accounts for 0.31% of the portfolio, ranked #59.

1015 Capital Partners first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

1015 Capital Partners held 1,450 shares of AbbVie worth $365K as of Q2 2026.
1015 Capital Partners sold 13 AbbVie shares in Q2 2026, an estimated $2.8K.
AbbVie made up 0.31% of 1015 Capital Partners's portfolio in Q2 2026, its #59 holding.
1015 Capital Partners first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.